Dr Jacob R Laskey, MD | |
1035 116th Ave Ne, Bellevue, WA 98004-4604 | |
(425) 635-6391 | |
Not Available |
Full Name | Dr Jacob R Laskey |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 11 Years |
Location | 1035 116th Ave Ne, Bellevue, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134562119 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | MD60720958 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Evergreenhealth Medical Center | Kirkland, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
King County Public Hospital District No 2 | 7618880097 | 481 |
News Archive
Being able to deliver drugs directly to diseased cells would improve options for treating diseases. Some radioactive isotopes are already approved to target cancers.
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
› Verified 3 days ago
Entity Name | King County Public Hospital District No 2 |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
Being able to deliver drugs directly to diseased cells would improve options for treating diseases. Some radioactive isotopes are already approved to target cancers.
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
› Verified 3 days ago
Entity Name | Overlake Hospital Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1861432726 PECOS PAC ID: 9234023433 Enrollment ID: O20040210000160 |
News Archive
Being able to deliver drugs directly to diseased cells would improve options for treating diseases. Some radioactive isotopes are already approved to target cancers.
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
› Verified 3 days ago
Entity Name | Overlake Medical Clinics Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
Being able to deliver drugs directly to diseased cells would improve options for treating diseases. Some radioactive isotopes are already approved to target cancers.
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Jacob R Laskey, MD 1035 116th Ave Ne, Bellevue, WA 98004 Ph: (425) 635-6391 | Dr Jacob R Laskey, MD 1035 116th Ave Ne, Bellevue, WA 98004-4604 Ph: (425) 635-6391 |
News Archive
Being able to deliver drugs directly to diseased cells would improve options for treating diseases. Some radioactive isotopes are already approved to target cancers.
Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).
Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells - a small population of cells within tumors that perpetuate cancer growth - conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.
A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.
Provepharm, a French company specialized in the development of pharmaceutical applications, today announces that Daiichi Sankyo, Co. Ltd., a global pharmaceutical firm, has filed an NDA (New Drug Application) for the development and marketing of the injectable Methylene Blue medicinal product in Japan, made out of Provepharm's Proveblue Methylene Blue active substance.
› Verified 3 days ago
Ted W Farrand, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-1331 | |
Dr. Ashok Shimoji-krishnan, MD, MPH Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 13451 Se 36th St, Bellevue, WA 98006 Phone: 425-562-1337 Fax: 425-562-3802 | |
Dr. Romelia Perez, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1611 116th Ave Ne, Suite 132, Bellevue, WA 98004 Phone: 206-795-9797 | |
Dr. Richard Cecil Geary Iii, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1750 112th Ave Ne, B102, Bellevue, WA 98004 Phone: 425-688-5460 Fax: 425-739-4667 | |
Dr. Edward William Freedman, MD Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 1621 114th Ave Se, Suite 221, Bellevue, WA 98004 Phone: 425-455-9900 Fax: 425-688-9987 | |
Ms. Claire Pastor, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1400 112th Ave Se Ste 100, Bellevue, WA 98004 Phone: 425-462-9511 Fax: 425-462-8894 | |
Dr. Megan Christine Riddle, MD PHD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1231 116th Ave Ne Ste 350, Bellevue, WA 98004 Phone: 425-454-1010 Fax: 425-880-5816 |